Comparative bioavailability of single‐dose zavegepant during and between migraine attacks: A phase 1, randomized, open‐label, fixed‐sequence, two‐period study

To compare the rate and extent of absorption of zavegepant 10 mg (therapeutic dose) or 20 mg (supratherapeutic dose) nasal spray during a migraine attack versus non-migraine period, assess safety, and explore efficacy and the relationship between zavegepant concentration and therapeutic response.